Equities

Atect Corp

4241:TYO

Atect Corp

Actions
IndustrialsGeneral Industrials
  • Price (JPY)684.00
  • Today's Change-5.00 / -0.73%
  • Shares traded12.50k
  • 1 Year change+17.53%
  • Beta1.0607
Data delayed at least 20 minutes, as of May 01 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

atect corporation mainly manufactures and sells hygiene inspection equipment. The Powder Injection Molding (PIM) segment mainly manufactures and sells auxiliary agents for injection molding processing, such as binders, as well as ceramics heat sinks. The Semiconductor Material segment manufactures and sells spacer tapes, which are protection materials of tape automated bonding (TAB) tapes and chip on film (COF) tapes. The Hygiene Inspection Equipment segment manufactures and sells reagents and medium series, and disposable petri dishes, as well as other containers.

  • Revenue in JPY (TTM)3.20bn
  • Net income in JPY114.29m
  • Incorporated1969
  • Employees96.00
  • Location
    Atect Corp3275-1, Kamihaneda-choHIGASHIOMI-SHI 527-0082JapanJPN
  • Phone+81 748203400
  • Fax+81 748203401
  • Websitehttps://www.atect.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PhoenixBio Co Ltd1.79bn113.89m1.92bn65.0023.941.0813.821.0719.8819.88401.02440.430.66251.527.1927,575,230.004.21-7.006.09-8.7767.4865.556.35-12.084.19--0.2199--60.3318.67227.16--14.18--
Modalis Therapeutics Corp0.00-2.39bn2.83bn37.00--1.86-----76.74-76.740.0041.390.00----0.00-92.78-29.19-99.33-30.02-------597.359.84--0.2301---100.00--11.50--135.50--
Muromachi Chemicals Inc6.12bn216.69m2.99bn205.0013.681.388.520.48953.4553.451,503.34527.871.203.833.7529,862,370.004.23--6.84--28.31--3.54--1.4526.200.4483--10.74---43.83------
Ribomic Inc62.64m-979.09m3.03bn25.00--0.8367--48.31-27.45-27.451.76100.390.0144--1.222,505,440.00-22.56-32.10-24.05-33.30-----1,563.14-1,688.5018.53--0.00---18.470.38091.88--10.04--
Atect Corp3.20bn114.29m3.06bn96.0026.651.456.630.955425.8525.85723.76474.920.57133.226.8533,330,020.002.042.032.832.7844.6847.693.573.840.7119--0.54629.40-4.032.10-6.3714.01-23.310.00
D.Western Therapeutics Institute Inc428.36m-812.41m3.34bn21.00--2.61--7.80-25.45-25.4513.4839.830.16070.43892.9820,398,290.00-31.09-13.06-33.75-14.3691.4494.29-193.39-72.5110.57--0.4089---4.407.90-89.07--7.08--
Kringle Pharma Inc70.58m-865.79m3.67bn13.00--1.50--51.95-158.59-158.5912.88374.930.024--0.73085,428,846.00-29.38-19.00-30.70-20.23-----1,226.76-156.5126.45-1,190.330.00---82.33---157.41------
OncoTherapy Science, Inc.901.22m-1.19bn3.70bn60.00--5.64--4.11-5.77-5.774.363.010.75895.3115.7415,020,330.00-100.44-50.21-132.58-55.41-9.03---132.35-331.973.29-258.180.00---1.6339.9756.50---57.92--
FunPep Co Ltd530.00k-933.42m3.85bn15.00--1.56--7,262.84-40.11-40.110.022594.970.0002----35,333.33-34.04-27.10-35.68-28.75-----176,116.20-815.8225.95-1,765.730.00---50.33-72.8020.39---13.14--
Human Metabolome Technologies Inc1.32bn282.64m3.87bn57.0013.672.1910.612.9347.8347.83223.67299.170.630214.234.7423,186,330.0013.48--16.73--65.03--21.39--4.27151.900.1103--6.21--6.71------
Kubota Pharmaceutical Holdings Co Ltd39.89m-1.49bn3.94bn12.00--1.48--98.80-26.80-26.800.717547.210.01070.531714.773,323,917.00-40.06-36.51-43.86-39.4770.48---3,734.55-13,528.8710.01--0.0512--383.24--26.11--24.38--
Perseus Proteomics Inc96.22m-1.12bn4.19bn24.00--2.61--43.59-95.57-95.578.18131.490.04241.8211.224,009,083.00-49.52-33.51-51.65-34.9589.0193.09-1,168.66-470.6317.58--0.00--30.96-20.89-31.38--228.18--
BrightPath Biotherapeutics Co Ltd118.00k-1.21bn4.24bn32.00--5.03--35,970.15-19.27-19.270.001911.920.00007--0.04233,687.50-71.34-42.65-89.42-44.49-433.0557.16-1,028,827.00-4,430.66---875.450.3929---65.73-56.89-0.0971---56.39--
Immuno-Biological Laboratories Co., Ltd.788.12m-192.71m4.38bn60.00--3.98--5.55-20.69-20.6984.62118.020.51440.87883.7813,135,280.00-12.58-15.11-14.85-17.6162.0656.66-24.45-50.043.490.4940.1774--22.710.9405-11.97------
Renascience Inc191.32m-331.66m4.45bn3.00--2.71--23.26-26.09-26.0915.05129.220.0851----63,772,000.00-14.74---15.49--85.75---173.36------0.1782---27.84---32.05------
Data as of May 01 2024. Currency figures normalised to Atect Corp's reporting currency: Japanese Yen JPY

Institutional shareholders

1.59%Per cent of shares held by top holders
HolderShares% Held
SPARX Asset Management Co., Ltd.as of 23 Jan 202367.30k1.52%
Nomura Asset Management Co., Ltd.as of 25 Oct 20223.20k0.07%
Samarang LLPas of 30 Jun 20220.000.00%
Data from 30 Jun 2022 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.